{"result": {"id": "abd72103-4d10-4617-ba8a-bdea4a18c319", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>EUROPEAN HEART JOURNAL<|>ORGANIZATION<|>Prestigious medical journal publishing cardiovascular research>  \n##  \n(\"entity\"<|>JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY<|>ORGANIZATION<|>Leading cardiology journal publishing clinical guidelines>  \n##  \n(\"entity\"<|>CIRCULATION<|>ORGANIZATION<|>American Heart Association journal publishing cardiovascular research>  \n##  \n(\"entity\"<|>NEW ENGLAND JOURNAL OF MEDICINE<|>ORGANIZATION<|>Premier medical journal publishing landmark clinical trials>  \n##  \n(\"entity\"<|>BRITISH MEDICAL JOURNAL<|>ORGANIZATION<|>Influential general medical journal>  \n##  \n(\"entity\"<|>JAMA<|>ORGANIZATION<|>Journal of the American Medical Association publishing clinical research>  \n##  \n(\"entity\"<|>EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY<|>ORGANIZATION<|>Specialized journal for vascular surgery research>  \n##  \n(\"entity\"<|>CHINESE MEDICAL JOURNAL<|>ORGANIZATION<|>Leading medical journal in China>  \n##  \n(\"entity\"<|>BOZKURT B<|>PERSON<|>Researcher co-authoring heart failure guidelines>  \n##  \n(\"entity\"<|>AGUILAR D<|>PERSON<|>Researcher contributing to cardiology guidelines>  \n##  \n(\"entity\"<|>ZIESCHE S<|>PERSON<|>Researcher involved in V-HeFT study>  \n##  \n(\"entity\"<|>SMITH R<|>PERSON<|>Researcher participating in heart failure trials>  \n##  \n(\"entity\"<|>O'CONNOR CM<|>PERSON<|>Researcher studying amlodipine in heart failure>  \n##  \n(\"entity\"<|>GHALI JK<|>PERSON<|>Investigator in heart failure clinical trials>  \n##  \n(\"entity\"<|>CLAGGETT B<|>PERSON<|>Researcher analyzing heart failure outcomes>  \n##  \n(\"entity\"<|>LEWIS EF<|>PERSON<|>Researcher studying ejection fraction in heart failure>  \n##  \n(\"entity\"<|>VADUGANATHAN M<|>PERSON<|>Researcher investigating sacubitril/valsartan>  \n##  \n(\"entity\"<|>BUTLER J<|>PERSON<|>Researcher studying empagliflozin in heart failure>  \n##  \n(\"entity\"<|>FILIPPATOS G<|>PERSON<|>Researcher involved in heart failure trials>  \n##  \n(\"entity\"<|>MCMURRAY JJV<|>PERSON<|>Researcher leading heart failure studies>  \n##  \n(\"entity\"<|>ADLER AI<|>PERSON<|>Researcher studying diabetes complications>  \n##  \n(\"entity\"<|>STRATTON IM<|>PERSON<|>Investigator in UKPDS diabetes study>  \n##  \n(\"entity\"<|>NEIL HA<|>PERSON<|>Researcher analyzing blood pressure outcomes>  \n##  \n(\"entity\"<|>ABOYANS V<|>PERSON<|>Researcher developing ESC vascular guidelines>  \n##  \n(\"entity\"<|>RICCO JB<|>PERSON<|>Researcher co-authoring peripheral artery disease guidelines>  \n##  \n(\"entity\"<|>BARTELINK MEL<|>PERSON<|>Researcher contributing to vascular guidelines>  \n##  \n(\"entity\"<|>ANDERSON JL<|>PERSON<|>Researcher compiling PAD management guidelines>  \n##  \n(\"entity\"<|>HALPERIN JL<|>PERSON<|>Researcher developing cardiovascular guidelines>  \n##  \n(\"entity\"<|>ALBERT NM<|>PERSON<|>Researcher involved in practice guidelines>  \n##  \n(\"entity\"<|>YUSUF S<|>PERSON<|>Principal investigator of HOPE study>  \n##  \n(\"entity\"<|>SLEIGHT P<|>PERSON<|>Researcher studying cardiovascular prevention>  \n##  \n(\"entity\"<|>BECKMAN JA<|>PERSON<|>Researcher studying diabetes and atherosclerosis>  \n##  \n(\"entity\"<|>CREAGER MA<|>PERSON<|>Researcher investigating vascular diseases>  \n##  \n(\"entity\"<|>LIBBY P<|>PERSON<|>Expert in atherosclerosis pathophysiology>  \n##  \n(\"entity\"<|>LIAPIS CD<|>PERSON<|>Researcher developing carotid stenosis guidelines>  \n##  \n(\"entity\"<|>BELL PR<|>PERSON<|>Researcher contributing to vascular surgery guidelines>  \n##  \n(\"entity\"<|>MIKHAILIDIS D<|>PERSON<|>Researcher involved in ESVS guidelines>  \n##  \n(\"entity\"<|>ZHENG Y<|>PERSON<|>Researcher studying hypertension in CKD>  \n##  \n(\"entity\"<|>CAI GY<|>PERSON<|>Researcher investigating kidney disease management>  \n##  \n(\"entity\"<|>CHEN XM<|>PERSON<|>Researcher analyzing hypertension control>  \n##  \n(\"relationship\"<|>AMERICAN COLLEGE OF CARDIOLOGY<|>JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY<|>Official journal publishing ACC guidelines<|>9>  \n##  \n(\"relationship\"<|>AMERICAN HEART ASSOCIATION<|>CIRCULATION<|>Flagship journal publishing AHA research<|>9>  \n##  \n(\"relationship\"<|>EUROPEAN SOCIETY OF CARDIOLOGY<|>EUROPEAN HEART JOURNAL<|>Official journal publishing ESC guidelines<|>9>  \n##  \n(\"relationship\"<|>YUSUF S<|>HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS<|>Led the landmark HOPE trial<|>9>  \n##  \n(\"relationship\"<|>VADUGANATHAN M<|>SCOTT D. SOLOMON<|>Collaborated on heart failure research<|>7>  \n##  \n(\"relationship\"<|>MCMURRAY JJV<|>STEFAN D. ANKER<|>Co-investigators in heart failure trials<|>8>  \n##  \n(\"relationship\"<|>ABOYANS V<|>EUROPEAN SOCIETY FOR VASCULAR SURGERY<|>Developed joint guidelines with ESVS<|>8>  \n##  \n(\"relationship\"<|>LIBBY P<|>BECKMAN JA<|>Co-authored research on diabetes and atherosclerosis<|>7>  \n##  \n(\"relationship\"<|>LIAPIS CD<|>EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY<|>Published carotid stenosis guidelines<|>8>  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751559062, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 1577, "prompt_tokens": 3843, "total_tokens": 5420, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3776}, "prompt_cache_hit_tokens": 3776, "prompt_cache_miss_tokens": 67}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: heart failure[J]. EurHeartJ,2021,42(36) :3599-3726.\n[571]  Heidenreich PA, Bozkurt B, Aguilar D,  et al.  2022 AHA/ ACC/HFSA guidelineforthe managementofheartfailure: ex- ecutivesummary: a reportoftheAmerican CollegeofCardiolo- gy/American HeartAssociationjointcommitteeonclinicalprac- ticeguidelines[J]. JAm CollCardiol,2022,79(17) :1757-1780.\n[572]  CohnJN, Ziesche S, SmithR, etal.  Effectofthe calcium an- tagonistfelodipine as supplementary vasodilator therapy in pa- tientswith chronicheartfailuretreated with enalapril: V-HeFT Ⅲ.  Vasodilator-Heart Failure Trial ( V-HeFT)  Study Group [J]. Circulation,1997,96(3) :856-863.\n[573]  PackerM, O'ConnorCM, GhaliJK, etal. Effectofamlodipine on morbidity and mortalityin severe chronicheartfailure.  Pro- spective Randomized Amlodipine Survival Evaluation  Study Group[J]. N EnglJ Med,1996,335(15) :1107-1114.\n[574]  SolomonSD, ClaggettB, LewisEF, etal. Influenceofejection fraction on outcomes and efficacy of spironolactone in patients withheartfailurewithpreserved ejection fraction[J]. EurHeart J,2016,37(5) :455-462.\n[575]  SolomonSD, VaduganathanM, LClaggettB, etal. Sacubitril/ valsartan acrossthespectrum ofejection fraction in heartfailure [J]. Circulation,2020,141(5) :352-361.\n[576]  AnkerSD, ButlerJ, FilippatosG, etal. Empagliflozin in heart failure with a preserved ejection fraction[J]. N EnglJ Med,  2021,385(16) :1451-1461.\n[577]  SolomonSD, McMurrayJJV, ClaggettB, etal. Dapagliflozinin heartfailure with mildly reduced or preserved ejection fraction [J]. N EnglJ Med,2022,387(12) :1089-1098.\n[578]  蒋雄京 ,杨进刚.  外周动脉病的治疗[J]. 中华内科杂志 ,2014,53\n(9) :755-756.\n[579]  AdlerAI, Stratton IM, NeilHA, etal. Association ofsystolic blood pressure with macrovascular and microvascular complica- tionsoftype2 diabetes(UKPDS36) : prospectiveobservational study[J]. BMJ,2000,321(7258) :412-419.\n[580]  AboyansV, Ricco JB, BartelinkMEL, etal.  2017ESC guide- lineson thediagnosisand treatmentofperipheralarterialdisea- ses, incollaborationwiththeEuropeanSocietyforVascularSur- gery(ESVS) : document covering atherosclerotic disease of ex- tracranialcarotid and vertebral, mesenteric,  renal, upper and\n\n\n\nlowerextremity arteriesEndorsed by: theEuropean Stroke Or- ganization(ESO)the taskforce forthe diagnosis and treatment ofperipheralarterialdiseasesoftheEuropeanSocietyofCardiol- ogy(ESC)  and of the European Society for Vascular Surgery (ESVS)[J]. EurHeartJ,2018,39(9) :763-816.\n[581]  AndersonJL, Halperin JL, AlbertNM, etal.  Managementof patientswithperipheralarterydisease(compilation of2005 and 2011ACCF/AHA guideline recommendations) : a reportofthe American College of Cardiology Foundation/American Heart Association TaskForce on Practice Guidelines[J]. Circulation,  2013,127(13) :1425-1443.\n[582]  HeartOutcomesPreventionEvaluationStudyInvestigators, Yusuf S, SleightP, etal. Effectsofan angiotensin-converting-enzyme inhibitor, ramipril, oncardiovasculareventsinhigh-riskpatients [J]. N EnglJ Med,2000,342(3) :145-153.\n[583]  BeckmanJA, CreagerMA, LibbyP.  Diabetesandatherosclero- sis:  epidemiology,  pathophysiology,  and management[ J].   JAMA,2002,287(19) :2570-2581.\n[584]  LiapisCD, BellPR, MikhailidisD, etal. ESVSguidelines.  In- vasive treatment for carotid stenosis:  indications,  techniques [J]. EurJVascEndovascSurg,2009,37(4Suppl) :1-19.\n[585]  Zheng Y, CaiGY,  Chen XM, et al.  Prevalence, awareness,  treatment, andcontrolofhypertensioninthenon-dialysischron- ickidney disease patients[J]. Chin MedJ (Engl) , 2013, 126\n(12) :2276-2280.\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>EURHEARTJ<|>ORGANIZATION<|>European Heart Journal, a medical journal publishing research on cardiovascular diseases>  \n##  \n(\"entity\"<|>AMERICAN COLLEGE OF CARDIOLOGY<|>ORGANIZATION<|>Professional medical society focused on cardiovascular care and research>  \n##  \n(\"entity\"<|>AMERICAN HEART ASSOCIATION<|>ORGANIZATION<|>Nonprofit organization dedicated to fighting heart disease and stroke>  \n##  \n(\"entity\"<|>V-HEFT STUDY GROUP<|>ORGANIZATION<|>Research group conducting the Vasodilator-Heart Failure Trial>  \n##  \n(\"entity\"<|>PROSPECTIVE RANDOMIZED AMLODIPINE SURVIVAL EVALUATION STUDY GROUP<|>ORGANIZATION<|>Research group evaluating amlodipine's effects on heart failure outcomes>  \n##  \n(\"entity\"<|>EUROPEAN SOCIETY OF CARDIOLOGY<|>ORGANIZATION<|>Professional organization for cardiology in Europe>  \n##  \n(\"entity\"<|>EUROPEAN SOCIETY FOR VASCULAR SURGERY<|>ORGANIZATION<|>Medical society focused on vascular surgery>  \n##  \n(\"entity\"<|>EUROPEAN STROKE ORGANIZATION<|>ORGANIZATION<|>Organization dedicated to stroke research and treatment>  \n##  \n(\"entity\"<|>HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS<|>ORGANIZATION<|>Research group studying cardiovascular event prevention>  \n##  \n(\"entity\"<|>PAUL A. HEIDENREICH<|>PERSON<|>Researcher and co-author of heart failure guidelines>  \n##  \n(\"entity\"<|>JOHN N. COHN<|>PERSON<|>Researcher involved in the V-HeFT study>  \n##  \n(\"entity\"<|>MILTON PACKER<|>PERSON<|>Researcher leading the amlodipine survival evaluation study>  \n##  \n(\"entity\"<|>SCOTT D. SOLOMON<|>PERSON<|>Researcher studying heart failure treatments>  \n##  \n(\"entity\"<|>STEFAN D. ANKER<|>PERSON<|>Researcher investigating empagliflozin in heart failure>  \n##  \n(\"entity\"<|>V-HEFT<|>EVENT<|>Clinical trial studying vasodilator therapy in heart failure>  \n##  \n(\"entity\"<|>UKPDS 36<|>EVENT<|>Study on blood pressure and diabetes complications>  \n##  \n(\"relationship\"<|>AMERICAN COLLEGE OF CARDIOLOGY<|>AMERICAN HEART ASSOCIATION<|>Collaborated on joint clinical practice guidelines for heart failure management<|>8>  \n##  \n(\"relationship\"<|>EUROPEAN SOCIETY OF CARDIOLOGY<|>EUROPEAN SOCIETY FOR VASCULAR SURGERY<|>Co-authored guidelines on peripheral arterial diseases<|>7>  \n##  \n(\"relationship\"<|>SCOTT D. SOLOMON<|>V-HEFT<|>Contributed to research on heart failure treatments<|>6>  \n##  \n(\"relationship\"<|>MILTON PACKER<|>PROSPECTIVE RANDOMIZED AMLODIPINE SURVIVAL EVALUATION STUDY GROUP<|>Led the study on amlodipine in heart failure<|>9>  \n##  \n(\"relationship\"<|>JOHN N. COHN<|>V-HEFT STUDY GROUP<|>Conducted research on vasodilator therapy in heart failure<|>8>  \n##  \n(\"relationship\"<|>STEFAN D. ANKER<|>EURHEARTJ<|>Published research on heart failure in the European Heart Journal<|>5>  \n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_fa60d5d834e2b98dee6043b48154791f1a96d971ce8d1d80bdfe60436de32087_v2"}